Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the ...

Medigene has said it will cut 40% of its workforce and delay the start of clinical trials of its lead asset as it re-jigs its ...

Medicare coverage would reduce out-of-pocket costs for AOMs – which can currently be as high as $1,000 a month - by as much ...

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, ...

The pharmaceutical industry operates under a complex regulatory landscape, balancing government oversight with self-imposed ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...

The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...